PHARMACOLOGIC STUDY OF 3-HOUR 135 mg m^-2 PACLITAXEL IN PLATINUM PRETREATED PATIENTS WITH ADVANCED OVARIAN CANCER

By Panday V.R.N.A.N.N.A.N.   Huizing M.T.   van WARMERDAM L.J.C.   Dubbelman R.C.   Mandjes I.   Schellens J.H.M.   Huinink W.W.T.E.N.B.O.K.K.E.L.   Beijnen J.H.  

Pharmacological Research, Vol. 38, Iss. 3, 1998-01 ,pp. : 231-236

Academic Press

Access to resources Recommend Favorite

A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy

By Ramanathan Ramesh  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1591-1596

Springer Publishing Company

Access to resources Recommend Favorite

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-α administered as a 24-hour weekly infusion schedule in patients with advanced cancer

By Advani Ranjana   Lum Bert   Fisher George   Halsey Joanne   Geary Richard   Holmlund Jon   Kwoh T.   Dorr F.   Sikic Branimir  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 467-477

Springer Publishing Company

Access to resources Recommend Favorite

A time and motion analysis: potential costs savings associated with a 72-hour intravenous infusion of pantoprazole using the new 24-hour stable solution

By Mueller Tanja   Barkun Alan N.  

Drugs & Therapy Perspectives, Vol. 23, Iss. 3, 2007-03 ,pp. : 20-22

Adis International

Access to resources Recommend Favorite

NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies

By Dent S.   Gelmon K.   Chi K.   Jonker D.   Wainman N.   Capier C.   Chen E.   Lyons J.   Seymour L.  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1522-1529

Springer Publishing Company

Access to resources Recommend Favorite